Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5184427 | 0.85 | GABRA1 (0.55) | GABRA1GABRB2ALDH1A1TAAR1TP53 | |
| SCHEMBL1402232 | 0.76 | — | — | |
| SCHEMBL140570 | 0.75 | GABRA1 (0.50) | GABRA1GABRB2SMN1; SMN2PTGS2TAAR1 | |
| SCHEMBL29420847 | 0.75 | GABRA1 (0.50) | GABRA1GABRB2SMN1; SMN2PTGS2TAAR1 | |
| SCHEMBL5489439 | 0.74 | TAAR1 (0.54) | GABRA1GABRB2ALDH1A1SMN1; SMN2PTGS2 | |
| O-Xylene SCHEMBL28187928 | 0.74 | TSHR (0.59) | GABRA1GABRB2ALDH1A1PTGS2TAAR1 | |
| SCHEMBL40576 | 0.74 | — | — | |
| SCHEMBL29458957 | 0.74 | — | — | |
| Fluoride SCHEMBL896142 | 0.73 | CYP2A6 (0.47) | GABRA1GABRB2ALDH1A1CYP1A2CYP2A6 | |
| Fluoride SCHEMBL896144 | 0.73 | CYP2A6 (0.47) | GABRA1GABRB2ALDH1A1CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339700-B1 | PROCESS FOR THE PREPARATION OF BENZOTRIAZOLES | CIBA SC HOLDING AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| US-20070208165-A1 | Process for the preparation of benzotriazoles | FISCHER WALTER | 2007-09-06 | — | — | US | disclosed |
| US-20040019220-A1 | Process for the preparation of benzotriazoles | CIBA SPECIALTY CHEMICALS CORP. | 2004-01-29 | — | — | US | disclosed |
| CN-1461300-A | Process for preparing benzotriazoles | CIBA SC HOLDING AG (CH) | 2003-12-10 | — | — | CN | disclosed |
| EP-1339700-A1 | PROCESS FOR THE PREPARATION OF BENZOTRIAZOLES | Ciba SC Holding AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002024668-A1 | PROCESS FOR THE PREPARATION OF BENZOTRIAZOLES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208165-A1 | Process for the preparation of benzotriazoles | CBR1, CCNT1, CYP1B1 | GABRA1 485/4885GABRB2 1064/4885ALDH1A1 408/4885 |
| US-20040019220-A1 | Process for the preparation of benzotriazoles | SULT1E1, SULT1A1, CYP1B1 | GABRA1 681/4885GABRB2 1080/4885ALDH1A1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.